TCAs, SNRIs, and alpha-2-delta ligands remain first-line treatments for neuropathic pain, while newer options like rTMS and ...

Explore new neuropathic pain therapies in this new study, and discover key updates and clinical recommendations.

Scientists from Weill Cornell Medicine and the Burke Neurological Institute have found a new drug that may help people who ...

Urcosimod phase 2 trial treating Neuropathic Corneal Pain ("NCP”) patients was initiated in October 2024 and designed as a ...

Regular physical activity helps cancer patients manage fatigue, pain, brain fog, emotional distress, and heart damage during ...

Bruce Hammock, a world-class scientist with worldwide impact, grew up in Little Rock, Arkansas, where he collected insects ...

OKYO Pharma's phase 2 trial for treating neuropathic corneal pain with urcosimod has been early closed; analysis of 17 patients is planned. OKYO Pharma has initiated a Phase 2 trial for urcosimod ...

Urcosimod is a lipid conjugated ChemR23 chemerin peptide agonist that is designed to reduce inflammation and pain in the eye.

OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod ...

Urcosimod phase 2 trial treating Neuropathic Corneal Pain (“NCP”) patients was initiated in October 2024 and designed as a double-masked, randomized, 12-week placebo-controlled trial.

Discover How the Nooro Foot Massager Combines Smart NMES Technology with Portable Design to Support Circulation, Ease Foot ...